MediPal Holdings (7459) Fundamentals 2026 — P/E 13.9x, Revenue Analysis | SniperIQ
MediPal Holdings (7459) is a JP-listed Healthcare company in Medical - Distribution with a market capitalization of ¥588.0B, trading at ¥2872.50 on the JPX. This SniperIQ fundamentals page covers MediPal Holdings's valuation (P/E 13.9x, P/B 0.9x), profitability (net margin 1.1%), revenue (¥3.82T in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MediPal Holdings's market cap?
MediPal Holdings (7459) has a market capitalization of approximately ¥588.0B, trading at ¥2872.50 on the JPX. Market cap moves with the live share price.
What is MediPal Holdings's P/E ratio?
MediPal Holdings's trailing twelve-month P/E ratio is 13.9x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MediPal Holdings?
MediPal Holdings runs a net profit margin of 1.1%, a gross margin of 6.5%, and an operating margin of 1.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MediPal Holdings generate?
MediPal Holdings reported revenue of ¥3.82T for fiscal year 2026, with net income of ¥42.5B and earnings per share (EPS) of 206.67. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MediPal Holdings pay a dividend?
MediPal Holdings offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is MediPal Holdings financially healthy?
MediPal Holdings carries a debt-to-equity ratio of 0.00x and a current ratio of 1.28x, with a market beta of -0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MediPal Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MediPal Holdings (7459) the key facts are: market cap ¥588.0B, P/E 13.9x, revenue ¥3.82T, 52-week range 2401-3070. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MediPal Holdings's full fundamentals live
Get MediPal Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.